Karyopharm Warns of Going-Concern Risk Without New Funding by Mid-October
Karyopharm skipped a $15.8M loan payment and won a pause until Oct. 15. Cash may last only that long without a new raise or deal.
/ 5 items
#KPTI↓
Karyopharm Shares Plunge After Selinexor Misses in Endometrial Cancer Trial
Karyopharm seeks accelerated FDA approval for selinexor combined with ruxolitinib—the potential first novel combo therapy for myelofibrosis patients.
Karyopharm Shares Plunge After $3.7M Executive Cash Retention Program
RBC calls the drop overdone and sees it as a buying opportunity.
Half the Patients Saw Dramatic Spleen Shrinkage: SENTRY Trial Shows Strong Results (With One Notable Miss) for New Myelofibrosis Combo
Karyopharm’s (KPTI) SENTRY trial delivers strong spleen reduction and promising survival data with selinexor + ruxolitinib — though symptom improvement was not superior. $30M cash boost extends runway into late 2026.
H.C. Wainwright Upgrades Karyopharm to Buy on Strategic Financing
H.C. Wainwright upgrades Karyopharm to Buy with $15 price target following strategic financing that extends cash runway beyond Phase 3 SENTRY trial results.